Header Logo

Connection

Douglas Golenbock to Glycolipids

This is a "connection" page, showing publications Douglas Golenbock has written about Glycolipids.
Connection Strength

0.952
  1. Meng J, Drolet JR, Monks BG, Golenbock DT. MD-2 residues tyrosine 42, arginine 69, aspartic acid 122, and leucine 125 provide species specificity for lipid IVA. J Biol Chem. 2010 Sep 03; 285(36):27935-43.
    View in: PubMed
    Score: 0.348
  2. Delude RL, Savedra R, Zhao H, Thieringer R, Yamamoto S, Fenton MJ, Golenbock DT. CD14 enhances cellular responses to endotoxin without imparting ligand-specific recognition. Proc Natl Acad Sci U S A. 1995 Sep 26; 92(20):9288-92.
    View in: PubMed
    Score: 0.125
  3. Golenbock DT, Leggett JE, Rasmussen P, Craig WA, Raetz CR, Proctor RA. Lipid X protects mice against fatal Escherichia coli infection. Infect Immun. 1988 Apr; 56(4):779-84.
    View in: PubMed
    Score: 0.075
  4. Golenbock DT, Ebert S, Will JA, Proctor RA. Elimination and tissue distribution of the monosaccharide lipid A precursor, lipid X, in mice and sheep. Antimicrob Agents Chemother. 1988 Jan; 32(1):37-41.
    View in: PubMed
    Score: 0.073
  5. Golenbock DT, Will JA, Raetz CR, Proctor RA. Lipid X ameliorates pulmonary hypertension and protects sheep from death due to endotoxin. Infect Immun. 1987 Oct; 55(10):2471-6.
    View in: PubMed
    Score: 0.072
  6. Fitzgerald KA, Golenbock DT. Immunology. The shape of things to come. Science. 2007 Jun 15; 316(5831):1574-6.
    View in: PubMed
    Score: 0.071
  7. Oliveira AC, Peixoto JR, de Arruda LB, Campos MA, Gazzinelli RT, Golenbock DT, Akira S, Previato JO, Mendon?a-Previato L, Nobrega A, Bellio M. Expression of functional TLR4 confers proinflammatory responsiveness to Trypanosoma cruzi glycoinositolphospholipids and higher resistance to infection with T. cruzi. J Immunol. 2004 Nov 01; 173(9):5688-96.
    View in: PubMed
    Score: 0.059
  8. Lien E, Means TK, Heine H, Yoshimura A, Kusumoto S, Fukase K, Fenton MJ, Oikawa M, Qureshi N, Monks B, Finberg RW, Ingalls RR, Golenbock DT. Toll-like receptor 4 imparts ligand-specific recognition of bacterial lipopolysaccharide. J Clin Invest. 2000 Feb; 105(4):497-504.
    View in: PubMed
    Score: 0.042
  9. Delude RL, Savedra R, Yamamoto S, Golenbock DT. Use of CD14 transfected cells to study LPS-antagonist action. Prog Clin Biol Res. 1995; 392:487-97.
    View in: PubMed
    Score: 0.030
  10. Lynn WA, Raetz CR, Qureshi N, Golenbock DT. Lipopolysaccharide-induced stimulation of CD11b/CD18 expression on neutrophils. Evidence of specific receptor-based response and inhibition by lipid A-based antagonists. J Immunol. 1991 Nov 01; 147(9):3072-9.
    View in: PubMed
    Score: 0.024
  11. Birkland TP, Cornwell RD, Golenbock DT, Proctor RA. Comparative study of lipopolysaccharide-, lipid IVa-, and lipid X-induced tumor necrosis factor production in murine macrophage-like cell lines. Adv Exp Med Biol. 1990; 256:399-402.
    View in: PubMed
    Score: 0.021
  12. Campos MA, Almeida IC, Takeuchi O, Akira S, Valente EP, Proc?pio DO, Travassos LR, Smith JA, Golenbock DT, Gazzinelli RT. Activation of Toll-like receptor-2 by glycosylphosphatidylinositol anchors from a protozoan parasite. J Immunol. 2001 Jul 01; 167(1):416-23.
    View in: PubMed
    Score: 0.012
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.